Creative Medical Technology Holdings Inc.'s Immcelz (CELZ-101) has been awarded orphan drug designation by the FDA. Immcelz is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation.
Neuraminidase (NA) is an essential surface protein of influenza viruses with potential as an effective drug and vaccine target. However, knowledge of the NA antigenic landscape remains limited, and most current influenza vaccines induce antibodies against the surface glycoprotein hemagglutinin.
Imunon Inc. has released promising results from a live virus challenge study conducted by the Wistar Institute with IMNN-101 against the SARS-CoV-2 variant XBB.1.5. This study was conducted using the clinical vector that Imunon intends to bring into its phase I study during the second quarter, and showed IMNN-101 immunogenicity and protective activity in a live viral mouse challenge.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Glyprovac LLC US$467,000 to develop a maternal vaccine that targets Escherichia coli, a bacterial species responsible for a large portion of neonatal sepsis infections.
Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
OSE Immunotherapeutics SA disclosed a $713 million deal with Abbvie Inc. for preclinical-stage monoclonal antibody OSE-230, a potentially first-in-class therapy for treating a range of inflammatory diseases, while Idorsia Ltd. found a partner for two phase III-stage assets in Viatris Inc., as dealmaking continues strong in 2024.
Researchers recently conducted a study to identify small molecules slowing metabolism and mimicking states normally induced by hypothermia or hibernation. The final aim was the discovery of drugs to preserve living cells, tissues and organs ex vivo, and potentially in vivo.
Baseimmune Ltd. has closed $11.3 million (£9 million) in series A funding. The company uses proprietary, deep learning artificial intelligence (AI) to predict future pathogen mutations to generate novel vaccines.
Scientists from the University of Bern have reported preclinical data on KiH_E07_79, a designed ankyrin repeat protein (DARPin) consisting of an Fc fusion construct comprising E07, an immunoglobulin E (IgE)-binding protein, and E2_79, an IgE disruptive domain, fused to an IgG Fc domain via a GS-rich linker.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded US$ 2.2 million to Limmatech Biologics AG to advance the development of its novel vaccine candidate to prevent Neisseria gonorrhoeae infections.
RSS
